Valuation Fate Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
2.110 ^USD	+0.96%		+17.88%	+114.74%

10-12	Fate Therapeutics, Inc. Announces Appointment of Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, Effective October 12, 2026	CI
09-25	Fate Therapeutics Receives $15.0 Million California Institute For Regenerative Medicine CLIN2 Grant To Support Advancement Of RECLAIM-LN	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	5,587	980.4	368.8	187.9	113.3	252.8	-	-
Change	-	-82.45%	-62.39%	-49.04%	-39.69%	123.05%	-	-
Enterprise Value (EV)	4,971	544.2	53.6	-118.8	113.3	252.8	252.8	252.8
Change	-	-89.05%	-90.15%	-321.66%	195.41%	123.05%	0%	0%
P/E	-26.1x	-3.47x	-2.28x	-1.01x	-0.85x	-1.98x	-2.04x	-1.88x
PBR	8.25x	2.03x	0.98x	0.59x	-	-	-	-
PEG	-	-0.1x	0.1x	-	0x	0.28x	0.66x	-0.22x
Capitalization / Revenue	100x	10.2x	5.8x	13.8x	17.1x	44.8x	53x	63.1x
EV / Revenue	0x	0x	0x	-0x	0x	44.8x	53x	63.1x
EV / EBITDA	-0x	-0x	-0x	0x	-0x	-2.12x	-1.65x	-
EV / EBIT	-0x	-0x	-0x	0x	-0x	-1.85x	-1.67x	-1.41x
EV / FCF	-0x	-0x	-0x	0x	-0x	-2.28x	-2.14x	-1.86x
FCF Yield	-3.82%	-28.9%	-37.5%	-65.8%	-98.8%	-43.9%	-46.7%	-53.8%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-2.24	-2.91	-1.64	-1.64	-1.15	-1.068	-1.035	-1.124
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	55.85	96.3	63.53	13.63	6.646	5.649	4.767	4.008
EBITDA ¹	-211.1	-294.6	-172.2	-191.3	-134.8	-119.3	-153.1	-
EBIT ¹	-217	-308.4	-190.5	-210.3	-147.7	-136.4	-151.7	-178.9
Net income ¹	-212.2	-281.7	-160.9	-186.3	-136.3	-128.8	-146	-179
Net Debt	-615.9	-436.2	-315.2	-306.7	-	-	-	-
Reference price ²	58.510	10.090	3.740	1.650	0.983	2.110	2.110	2.110
Nbr of stocks (in thousands)	95,494	97,170	98,602	113,894	115,352	119,821	-	-
Announcement Date	2/28/22	2/28/23	2/26/24	3/5/25	2/26/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
FATE THERAPEUTICS, INC.	-1.98x	-	-	-.--%	253M
WUXI APPTEC CO., LTD.	18.83x	6.63x	13.18x	1.58%	64.69B
ARGENX SE	30.16x	8x	26.2x	0.05%	54.78B
LONZA GROUP AG	36.79x	6.53x	19.51x	0.88%	53.49B
IQVIA HOLDINGS INC.	35.59x	3.45x	14.87x	-.--%	45.98B
BEONE MEDICINES AG	49.71x	5.74x	31.52x	-.--%	42.94B
REVOLUTION MEDICINES, INC.	-19.41x	187.75x	-20.66x	-.--%	40.08B
CELLTRION, INC.	28.93x	8.21x	21.27x	0.37%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	27.67x	5.83x	15.12x	-.--%	23.97B
GENMAB A/S	32.66x	5.97x	20.09x	-.--%	23.67B
Average	23.90x	26.46x	15.68x	0.29%	38.34B
Weighted average by Cap.	26.70x	25.33x	15.90x	0.43%